- Yale HematologySmilow Cancer Hospital at Yale New Haven35 Park StreetNew Haven, CT 06511
Tarsheen Sethi, MD, MSc
Hematologic Oncology, Leukemia & Lymphoma, Hematology
Telehealth is available
Patient type treated
Adult
Accepting new patients
Yes
Referral required
From patients or physicians
Board Certified in
Internal Medicine, Hematology (Internal Medicine)
, and Medical Oncology
Biography
Tarsheen Sethi, MD, MSCI (master of science in clinical investigation), is a hematologist who specializes in treating patients with Hodgkin and non-Hodgkin lymphoma—cancers that begin in white blood cells called lymphocytes, which are an important part of the immune system.
An active researcher, Dr. Sethi focuses on treatments using new drugs and multi-drug combinations on all types of lymphomas. Some of her research addresses treatment of a rare category of lymphomas, hastening patient referrals, improving quality of life, and coordinating the use of different drugs.
As the understanding of cancer has become more specific and treatments more complex and targeted, Dr. Sethi has worked to help build a database of information on chemotherapy treatments that is shared freely throughout the world.
Titles
- Assistant Professor of Medicine (Hematology)
- Director, Yale Affiliated Hospital Program for Hematology Section, Internal Medicine
Education & Training
- Clinical Fellow and Advanced FellowVanderbilt University Medical Center (2018)
- MScVanderbilt University, Clinical Investigation (2018)
- Intern and Resident PhysicianUniversity of Louisville (2013)
- Chief ResidentMaulana Azad Medical College (2009)
- MDMaulana Azad Medical College (2008)
- Resident PhysicianMaulana Azad Medical College (2008)
- MBBSMaulana Azad Medical College (2005)
Additional Information
Honors & Recognitions
- AACR/ASCO VAIL Methods in Clinical Cancer Research (MCCR) : (2017)
- Abstract Achievement Award: American Society of Hematology (2016)
- Post Doctoral Fellowship in Translational Medicine and Therapeutics : Pharmaceutical Research and Manufacturers of America (PhRMA) Foundation (2013)
- Award for the highest score in the Internal Medicine in-service exam among PGY3 residents: University of Louisville (2013)
- Award for the highest score in the Internal Medicine in- service exam among PGY2 residents: University of Louisville (2012)
- Award for the highest score in the Internal Medicine in- service exam among PGY1 residents: University of Louisville (2011)
Professional Service
- New England Hematologic Malignancies Symposium (2023 - Present): Abstract Reviewer
- The DeLuca Center for Innovation in Hematology Research Seminar Series (2023 - Present): Co-Director
- “ASCO Reading Room" section of MedPage Today (2023 - Present): Reviewer
- HIV-Cancer Focus Group (2022 - Present): Member
- Yale Cancer Center Protocol Review Committee (PRC) (2022 - Present): Member
- Yale Affiliated Hospitals Program (YAHP)-Hematology (2022 - Present): Director
- Cancer Journal (2021 - Present): Reviewer
- American Society of Hematology Annual Meeting 2021 (2021): Session Name: 624. Hodgkin Lymphomas and T/NK cell Lymphomas: T/NK Cell Lymphoma Relapsed Therapy Session Date: Monday, December 13, 2021 Session Time: 10:30 AM - 12:00 PM Eastern time Room: Georgia World Congress Center, Hall A1
- National Comprehensive Cancer Center (NCCN) Histiocytosis Panel (2019 - 2020): Member
- HemOnc.org Aggressive Lymphomas Section (2019 - Present): Reviewing Editor
Publications
- Straining R, Foss F, Schiffer M, Amin K, Agarwal S, Isufi I, Huntington S, Kothari S, Seropian S, Girardi M, Sethi T. Real World Data on Efficacy and Safety of EPOCH in T-Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia 2024 PMID: 39368885, DOI: 10.1016/j.clml.2024.09.005.
- Epperla N, Huang Y, Cashen A, Vaughn J, Hanel W, Badar T, Barta S, Caimi P, Sethi T, Reddy N, Karmali R, Bello C, Chavez J, Kothari S, Hernandez-Ilizaliturri F, Svoboda J, Lansigan F, Glenn M, Cohen J, Sorge C, Christian B, Herrera A, Hamadani M, Costa L, Xavier A. Evaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantation. Blood Advances 2024, 8: 5458-5466. PMID: 39213424, PMCID: PMC11532746, DOI: 10.1182/bloodadvances.2024013743.
- Warner J, Bakow B, Brown A, Choe J, Fan E, Ganta T, Glover M, Hadfield M, Hilton C, Khaki A, Kothari S, Lythgoe M, Nagpal S, Nguyen R, Noyd D, Riaz I, Rooney M, Sethi T, Singhi E, Rubinstein S. Characterizing the authorship of phase 3 randomized clinical trials in oncology, 1960-2023. Journal Of Clinical Oncology 2024, 42: 11079-11079. DOI: 10.1200/jco.2024.42.16_suppl.11079.
- Jain S, Zauderer M, Sethi T, Schoen M, Rubinstein S, Nguyen R, Nagpal S, Mohan S, Madireddy S, Lythgoe M, Liang W, Kulkarni A, Kothari S, Hilal T, Hadfield M, Goyal G, Ganta T, Dholaria B, Brown A, Warner J. Evaluation of the study of control arms in randomized clinical trials of cancer. Journal Of Clinical Oncology 2024, 42: 11023-11023. DOI: 10.1200/jco.2024.42.16_suppl.11023.
- Di M, Long J, Kothari S, Sethi T, Zeidan A, Podoltsev N, Shallis R, Wang R, Ma X, Huntington S. Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: a population-based analysis. Haematologica 2023, 108: 2218-2223. PMID: 36655436, PMCID: PMC10388284, DOI: 10.3324/haematol.2022.282252.
- Primary Cutaneous LymphomasPerez & Brady's Principles and Practice of Radiation Oncology (8th edition). In Press.
- Means, Robert T.(2023). Wintrobe's Clinical Hematology (15th Edition). Lippincott Williams & Wilkins (LWW).
- Dittus C, Grover N, Sethi T, Cohen JB, Voloschin A, Rabadey J, Tan X, Beaven A, Park SI. A multicenter, real‐world analysis of primary central nervous system lymphoma in those with and without human immunodeficiency virus. EJHaem 2022, 3: 734-738. PMID: 36051081, PMCID: PMC9421958, DOI: 10.1002/jha2.474.
- Gisriel SD, Yuan J, Braunberger RC, Maracaja DLV, Chen X, Wu X, McCracken J, Chen M, Xie Y, Brown LE, Li P, Zhou Y, Sethi T, McHenry A, Hauser RG, Paulson N, Tang H, Hsi ED, Wang E, Zhang QY, Young KH, Xu ML, Pan Z. Human herpesvirus 8-negative effusion-based large B-cell lymphoma: a distinct entity with unique clinicopathologic characteristics. Modern Pathology 2022, 35: 1411-1422. PMID: 35562413, PMCID: PMC9926946, DOI: 10.1038/s41379-022-01091-x.
- Sethi T, Montanari F, Foss F. Safety considerations with the current treatments for peripheral T-cell lymphoma. Expert Opinion On Drug Safety 2022, 21: 653-660. PMID: 35129014, DOI: 10.1080/14740338.2022.2036120.
- DeVita, Hellman, and Rosenberg's Cancer Principles & Practice of Oncology( 2022,12th edition). Lippincott Williams & Wilkins (LWW).
- Rubinstein SM, Sethi T, Venepalli NK, Gyawali B, Schwartz C, Rivera DR, Yang PC, Warner JL. Chemotherapy Knowledge Base Management in the Era of Precision Oncology. JCO Clinical Cancer Informatics 2021, 5: 30-35. PMID: 33411619, PMCID: PMC8189622, DOI: 10.1200/cci.20.00076.
- Allen P, Goyal S, Greenwell I, Scribner J, Rangarajan S, Mehta A, O'Leary C, Niyogusaba T, Huen A, Switchenko J, Tarabadkar E, Ayers A, Krishnasamy S, Porcu P, Sethi T, Iyer S, Lechowicz M. No Difference in Survival Among Black Patients with Mycosis Fungoides and Sézary Syndrome: A Multicenter Retrospective Analysis. Blood 2021, 138: 2441. DOI: 10.1182/blood-2021-151911.
- Sethi T, Gerstein R, Schiffer M, Amin K, Agarwal S, Foss F. EPOCH Is a Safe and Effective Treatment Option for Aggressive T-Cell Lymphomas. Blood 2021, 138: 4547. DOI: 10.1182/blood-2021-151238.
- Hill B, Roth C, Kositsky R, Dave T, Love C, McKinney M, Galal A, Neff J, Mian A, Kendall E, Ondrejka S, Chiaramonte M, Bhagat G, Ofori K, Reshef R, Kovach A, Sethi T, Mason E, Bhaskar S, Oluwole O, Pallas C, Ghosh N, Ferdman R, Chen G, Hernandez-Ilizaliturri F, Zurko J, Cunningham A, Shah N, Hu B, Stephens D, Ghosh M, Bailey N, Patel K, Pagel J, Kannan K, Hsi E, Vaidya R, Ip A, Goy A, Kambhampati S, Ohgami R, Andreadis C, Thacker E, Rozzi C, Parker C, Happ L, Dave S. Impact of Molecular Features of Diffuse Large B-Cell Lymphoma on Treatment Outcomes with Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy. Blood 2021, 138: 165. DOI: 10.1182/blood-2021-145764.
- Dittus C, Grover N, Sethi T, Cohen J, Voloschin A, Rabadey J, Tan X, Beaven A, Park S. A Multicenter, Real World Analysis of Primary Central Nervous System Lymphoma in Those with and without Human Immunodeficiency Virus. Blood 2021, 138: 1457. DOI: 10.1182/blood-2021-145133.
- Desai M, Sethi T, Yenamandra A, Morgan D, Thompson M, Reddy N, Kovach A. Primary sinonasal large B cell lymphoma is as histopathologically heterogeneous as systemic large B cell lymphoma but may show subtype-specific tropism for specific sinonasal anatomic sites. Journal Of Hematopathology 2021, 14: 269-275. DOI: 10.1007/s12308-021-00473-5.
- Sethi TK, Montanari F, Foss F, Reddy N. How we treat advanced stage cutaneous T‐cell lymphoma – mycosis fungoides and Sézary syndrome. British Journal Of Haematology 2021, 195: 352-364. PMID: 33987825, DOI: 10.1111/bjh.17458.
- Roy S, Sethi TK, Taylor D, Kim YJ, Johnson DB. Breakthrough concepts in immune-oncology: Cancer vaccines at the bedside. Journal Of Leukocyte Biology 2020, 108: 1455-1489. PMID: 32557857, DOI: 10.1002/jlb.5bt0420-585rr.
- Warner J, Sethi T, Rivera D, Venepalli N, Osterman T, Khaki A, Rubinstein S. Trends in FDA cancer registration trial design over time, 1969-2020. Journal Of Clinical Oncology 2020, 38: 2060-2060. DOI: 10.1200/jco.2020.38.15_suppl.2060.
- Sethi T, Kovach A, Mason E, Chen H, Moyo T, Oluwole O, Morgan D, Reddy N. Combination of Nivolumab, Lenalidomide and Rituximab in Relapsed/Refractory Non-Germinal Center Diffuse Large B Cell Lymphoma: Results from a Dose-Escalation Cohort. Blood 2019, 134: 4100. DOI: 10.1182/blood-2019-129634.
- Epperla N, Costa L, Vaughn J, Hanel W, Raya S, Cashen A, Sarmad R, Badar T, Hamadani M, Liu Y, Barta S, Caimi P, Sethi T, Reddy N, Burkart M, Karmali R, Bello C, Chavez J, Kothari S, Hernandez-Ilizaliturri F, Ballard H, Svoboda J, Emery L, Lansigan F, Glenn M, Churnetski M, Cohen J, Sorge C, Xavier A. Impact of Novel Agents on Outcomes of Patients with Classical Hodgkin Lymphoma and Primary Treatment Failure. Blood 2019, 134: 1554. DOI: 10.1182/blood-2019-129199.
- Sethi TK, Kovach AE, Grover NS, Huang LC, Lee LA, Rubinstein SM, Wang Y, Morgan DS, Greer JP, Park SI, Thompson-Arildsen M, Yenamandra A, Vnencak-Jones CL, Reddy NM. Clinicopathologic correlates of MYD88 L265P mutation and programmed cell death (PD-1) pathway in primary central nervous system lymphoma. Leukemia & Lymphoma 2019, 60: 2880-2889. PMID: 31184237, PMCID: PMC7280020, DOI: 10.1080/10428194.2019.1620942.
- Sethi TK, Morgan D. Hodgkin Lymphoma.J.P. Greer. (2019). Wintrobe’s Clinical Hematology (14th edition). Lippincott Williams & Wilkins (LWW).
- Aghighi M, Theruvath AJ, Pareek A, Pisani LL, Alford R, Muehe AM, Sethi TK, Holdsworth SJ, Hazard FK, Gratzinger D, Luna-Fineman S, Advani R, Spunt SL, Daldrup-Link HE. Magnetic Resonance Imaging of Tumor-Associated Macrophages: Clinical Translation. Clinical Cancer Research 2018, 24: 4110-4118. PMID: 29764855, PMCID: PMC6125171, DOI: 10.1158/1078-0432.ccr-18-0673.
- Treatment of newly diagnosed primary central nervous system lymphoma: current and emerging therapiesSethi TK, Reddy NM. Treatment of newly diagnosed primary central nervous system lymphoma: current and emerging therapies. Leukemia & Lymphoma 2018, 60: 6-18. PMID: 29741421, DOI: 10.1080/10428194.2018.1466296.
- Oke O, Sethi T, Goodman S, Phillips S, Decker I, Rubinstein S, Concepcion B, Horst S, Jagasia M, Kassim A, Harrell SL, Langone A, Lenihan D, Rawling KT, Slosky D, Cornell RF. Outcomes from Autologous Hematopoietic Cell Transplantation versus Chemotherapy Alone for the Management of Light Chain Amyloidosis. Transplantation And Cellular Therapy 2017, 23: 1473-1477. PMID: 28546074, DOI: 10.1016/j.bbmt.2017.05.020.
- Sethi TK, Basdag B, Bhatia N, Moslehi J, Reddy NM. Beyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic Malignancies. Current Hematologic Malignancy Reports 2017, 12: 257-267. PMID: 28233150, DOI: 10.1007/s11899-017-0369-y.
- Sethi T, Reddy N. Current and Emerging Drug Therapies in Chronic Lymphocytic Leukemia. TouchREVIEWS In Oncology & Haematology 2017, 13: 34. DOI: 10.17925/ohr.2017.13.01.34.
- Sethi T, Kovach A, Rubinstein S, Lee L, Wang Y, Morgan D, Greer J, Vnencak-Jones C, Reddy N. Correlation of Toll-like Receptor (TLR) and PD-1 Pathways in Central Nervous System Lymphoma: A Clinicopathological Study on Outcomes. Blood 2016, 128: 929. DOI: 10.1182/blood.v128.22.929.929.
- Sethi T, Nguyen V, Li S, Morgan D, Greer J, Reddy N. Differences in outcome of patients with syncytial variant Hodgkin lymphoma compared with typical nodular sclerosis Hodgkin lymphoma. Therapeutic Advances In Hematology 2016, 8: 13-20. PMID: 28042455, PMCID: PMC5167078, DOI: 10.1177/2040620716676256.
- Sethi T, Nguyen V, Li S, Morgan D, Greer J, Reddy N. Differences in Outcome of Patients with Syncytial Variant Hodgkin Lymphoma (HL) Compared with Typical Nodular Sclerosis HL. Clinical Lymphoma Myeloma & Leukemia 2016, 16: s68-s69. DOI: 10.1016/j.clml.2016.07.100.
- Reddy NM, Sethi TK. Beyond Epstein-Barr virus: genetic predisposition of natural killer T-cell lymphoma. The Lancet Oncology 2016, 17: 1176-1177. PMID: 27470080, DOI: 10.1016/s1470-2045(16)30205-4.
- Aghighi M, Boe J, Rosenberg J, Von Eyben R, Gawande RS, Petit P, Sethi TK, Sharib J, Marina NM, DuBois SG, Daldrup-Link HE. Three-dimensional Radiologic Assessment of Chemotherapy Response in Ewing Sarcoma Can Be Used to Predict Clinical Outcome. Radiology 2016, 280: 905-15. PMID: 26982677, PMCID: PMC5006736, DOI: 10.1148/radiol.2016151301.
- Ukaegbu O, Sethi T, Goodman S, Rubinstein S, Hung R, Jagasia M, Kassim A, Lacy S, Langone A, Lenihan D, Savani B, Slosky D, Cornell R. Autologous Hematopoietic Cell Transplant (AHCT) Offers Prolonged Progression Free and Overall Survival in Patients with Light Chain Amyloidosis (AL) Compared with Chemotherapy Alone. Transplantation And Cellular Therapy 2016, 22: s233-s234. DOI: 10.1016/j.bbmt.2015.11.642.
- Histology-Specific Uses of Tyrosine Kinase Inhibitors in Non-gastrointestinal Stromal Tumor SarcomasSethi TK, Keedy VL. Histology-Specific Uses of Tyrosine Kinase Inhibitors in Non-gastrointestinal Stromal Tumor Sarcomas. Current Treatment Options In Oncology 2016, 17: 11. PMID: 26931561, DOI: 10.1007/s11864-015-0382-0.
- Chen J, Lenihan D, Phillips S, Jagasia M, Goodman S, Kassim A, Lacy S, McDonagh K, Moslehi J, Sethi T, Slosky D, Ukaegbu O, Cornell R. Risk Factors for Cardiac Toxicities Associated with Proteasome Inhibitor Chemotherapy during Treatment of Multiple Myeloma. Blood 2015, 126: 5363. DOI: 10.1182/blood.v126.23.5363.5363.
- Sethi T, Nguyen V, Morgan D, Greer J, Reddy N. Interim Absolute Lymphocyte Count (ALC) As a Predictor of Survival in Hodgkin Lymphoma. Blood 2015, 126: 2640. DOI: 10.1182/blood.v126.23.2640.2640.
- Decker I, Ukaegbu O, Goodman S, Lenihan D, Hung R, Kassim A, Harrell S, McDonagh K, Phillips S, Rawling K, Rubinstein S, Sethi T, Cornell R. Six-Minute Walk Test As a Measure of Functional Change after Chemotherapy in Cardiac AL Amyloidosis. Blood 2015, 126: 1841. DOI: 10.1182/blood.v126.23.1841.1841.
- Sethi T, Nguyen V, Li S, Morgan D, Greer J, Reddy N. Differences in Outcome of Patients with Syncytial Variant Hodgkin Lymphoma (HL) Compared with Typical Nodular Sclerosis HL. Blood 2015, 126: 1441. DOI: 10.1182/blood.v126.23.1441.1441.
- Reddy N, Sethi T. Ibrutinib in chronic lymphocytic leukemia. International Journal Of Hematologic Oncology 2015, 4: 143-150. DOI: 10.2217/ijh.15.15.
- Sethi T, Alireza A, Kloecker G, Slone S. Multicentric Castleman Disease with Complete Duodenal Obstruction in an HIV Patient. Blood 2012, 120: 4834. DOI: 10.1182/blood.v120.21.4834.4834.
- Sethi TK, El-Ghamry MN, Kloecker GH. Radon and lung cancer. Clinical Advances In Hematology And Oncology 2012, 10: 157-64. PMID: 22402423.
- Kaul B, Sivaramakrishnan R, Mahapatra H, Sethi TK, Ahlawat R. Iron deficiency masquerading as idiopathic intracranial hypertension. BMJ Case Reports 2009, 2009: bcr0620080346. PMID: 21686848, PMCID: PMC3028304, DOI: 10.1136/bcr.06.2008.0346.
Departments and Programs
Locations
- Yale HematologySmilow Cancer Hospital at Yale New Haven35 Park StreetNew Haven, CT 06511
Biography
Tarsheen Sethi, MD, MSCI (master of science in clinical investigation), is a hematologist who specializes in treating patients with Hodgkin and non-Hodgkin lymphoma—cancers that begin in white blood cells called lymphocytes, which are an important part of the immune system.
An active researcher, Dr. Sethi focuses on treatments using new drugs and multi-drug combinations on all types of lymphomas. Some of her research addresses treatment of a rare category of lymphomas, hastening patient referrals, improving quality of life, and coordinating the use of different drugs.
As the understanding of cancer has become more specific and treatments more complex and targeted, Dr. Sethi has worked to help build a database of information on chemotherapy treatments that is shared freely throughout the world.
Titles
- Assistant Professor of Medicine (Hematology)
- Director, Yale Affiliated Hospital Program for Hematology Section, Internal Medicine
Education & Training
- Clinical Fellow and Advanced FellowVanderbilt University Medical Center (2018)
- MScVanderbilt University, Clinical Investigation (2018)
- Intern and Resident PhysicianUniversity of Louisville (2013)
- Chief ResidentMaulana Azad Medical College (2009)
- MDMaulana Azad Medical College (2008)
- Resident PhysicianMaulana Azad Medical College (2008)
- MBBSMaulana Azad Medical College (2005)
Additional Information
Honors & Recognitions
- AACR/ASCO VAIL Methods in Clinical Cancer Research (MCCR) : (2017)
- Abstract Achievement Award: American Society of Hematology (2016)
- Post Doctoral Fellowship in Translational Medicine and Therapeutics : Pharmaceutical Research and Manufacturers of America (PhRMA) Foundation (2013)
- Award for the highest score in the Internal Medicine in-service exam among PGY3 residents: University of Louisville (2013)
- Award for the highest score in the Internal Medicine in- service exam among PGY2 residents: University of Louisville (2012)
- Award for the highest score in the Internal Medicine in- service exam among PGY1 residents: University of Louisville (2011)
Professional Service
- New England Hematologic Malignancies Symposium (2023 - Present): Abstract Reviewer
- The DeLuca Center for Innovation in Hematology Research Seminar Series (2023 - Present): Co-Director
- “ASCO Reading Room" section of MedPage Today (2023 - Present): Reviewer
- HIV-Cancer Focus Group (2022 - Present): Member
- Yale Cancer Center Protocol Review Committee (PRC) (2022 - Present): Member
- Yale Affiliated Hospitals Program (YAHP)-Hematology (2022 - Present): Director
- Cancer Journal (2021 - Present): Reviewer
- American Society of Hematology Annual Meeting 2021 (2021): Session Name: 624. Hodgkin Lymphomas and T/NK cell Lymphomas: T/NK Cell Lymphoma Relapsed Therapy Session Date: Monday, December 13, 2021 Session Time: 10:30 AM - 12:00 PM Eastern time Room: Georgia World Congress Center, Hall A1
- National Comprehensive Cancer Center (NCCN) Histiocytosis Panel (2019 - 2020): Member
- HemOnc.org Aggressive Lymphomas Section (2019 - Present): Reviewing Editor
Publications
- Straining R, Foss F, Schiffer M, Amin K, Agarwal S, Isufi I, Huntington S, Kothari S, Seropian S, Girardi M, Sethi T. Real World Data on Efficacy and Safety of EPOCH in T-Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia 2024 PMID: 39368885, DOI: 10.1016/j.clml.2024.09.005.
- Epperla N, Huang Y, Cashen A, Vaughn J, Hanel W, Badar T, Barta S, Caimi P, Sethi T, Reddy N, Karmali R, Bello C, Chavez J, Kothari S, Hernandez-Ilizaliturri F, Svoboda J, Lansigan F, Glenn M, Cohen J, Sorge C, Christian B, Herrera A, Hamadani M, Costa L, Xavier A. Evaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantation. Blood Advances 2024, 8: 5458-5466. PMID: 39213424, PMCID: PMC11532746, DOI: 10.1182/bloodadvances.2024013743.
- Warner J, Bakow B, Brown A, Choe J, Fan E, Ganta T, Glover M, Hadfield M, Hilton C, Khaki A, Kothari S, Lythgoe M, Nagpal S, Nguyen R, Noyd D, Riaz I, Rooney M, Sethi T, Singhi E, Rubinstein S. Characterizing the authorship of phase 3 randomized clinical trials in oncology, 1960-2023. Journal Of Clinical Oncology 2024, 42: 11079-11079. DOI: 10.1200/jco.2024.42.16_suppl.11079.
- Jain S, Zauderer M, Sethi T, Schoen M, Rubinstein S, Nguyen R, Nagpal S, Mohan S, Madireddy S, Lythgoe M, Liang W, Kulkarni A, Kothari S, Hilal T, Hadfield M, Goyal G, Ganta T, Dholaria B, Brown A, Warner J. Evaluation of the study of control arms in randomized clinical trials of cancer. Journal Of Clinical Oncology 2024, 42: 11023-11023. DOI: 10.1200/jco.2024.42.16_suppl.11023.
- Di M, Long J, Kothari S, Sethi T, Zeidan A, Podoltsev N, Shallis R, Wang R, Ma X, Huntington S. Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: a population-based analysis. Haematologica 2023, 108: 2218-2223. PMID: 36655436, PMCID: PMC10388284, DOI: 10.3324/haematol.2022.282252.
- Primary Cutaneous LymphomasPerez & Brady's Principles and Practice of Radiation Oncology (8th edition). In Press.
- Means, Robert T.(2023). Wintrobe's Clinical Hematology (15th Edition). Lippincott Williams & Wilkins (LWW).
- Dittus C, Grover N, Sethi T, Cohen JB, Voloschin A, Rabadey J, Tan X, Beaven A, Park SI. A multicenter, real‐world analysis of primary central nervous system lymphoma in those with and without human immunodeficiency virus. EJHaem 2022, 3: 734-738. PMID: 36051081, PMCID: PMC9421958, DOI: 10.1002/jha2.474.
- Gisriel SD, Yuan J, Braunberger RC, Maracaja DLV, Chen X, Wu X, McCracken J, Chen M, Xie Y, Brown LE, Li P, Zhou Y, Sethi T, McHenry A, Hauser RG, Paulson N, Tang H, Hsi ED, Wang E, Zhang QY, Young KH, Xu ML, Pan Z. Human herpesvirus 8-negative effusion-based large B-cell lymphoma: a distinct entity with unique clinicopathologic characteristics. Modern Pathology 2022, 35: 1411-1422. PMID: 35562413, PMCID: PMC9926946, DOI: 10.1038/s41379-022-01091-x.
- Sethi T, Montanari F, Foss F. Safety considerations with the current treatments for peripheral T-cell lymphoma. Expert Opinion On Drug Safety 2022, 21: 653-660. PMID: 35129014, DOI: 10.1080/14740338.2022.2036120.
- DeVita, Hellman, and Rosenberg's Cancer Principles & Practice of Oncology( 2022,12th edition). Lippincott Williams & Wilkins (LWW).
- Rubinstein SM, Sethi T, Venepalli NK, Gyawali B, Schwartz C, Rivera DR, Yang PC, Warner JL. Chemotherapy Knowledge Base Management in the Era of Precision Oncology. JCO Clinical Cancer Informatics 2021, 5: 30-35. PMID: 33411619, PMCID: PMC8189622, DOI: 10.1200/cci.20.00076.
- Allen P, Goyal S, Greenwell I, Scribner J, Rangarajan S, Mehta A, O'Leary C, Niyogusaba T, Huen A, Switchenko J, Tarabadkar E, Ayers A, Krishnasamy S, Porcu P, Sethi T, Iyer S, Lechowicz M. No Difference in Survival Among Black Patients with Mycosis Fungoides and Sézary Syndrome: A Multicenter Retrospective Analysis. Blood 2021, 138: 2441. DOI: 10.1182/blood-2021-151911.
- Sethi T, Gerstein R, Schiffer M, Amin K, Agarwal S, Foss F. EPOCH Is a Safe and Effective Treatment Option for Aggressive T-Cell Lymphomas. Blood 2021, 138: 4547. DOI: 10.1182/blood-2021-151238.
- Hill B, Roth C, Kositsky R, Dave T, Love C, McKinney M, Galal A, Neff J, Mian A, Kendall E, Ondrejka S, Chiaramonte M, Bhagat G, Ofori K, Reshef R, Kovach A, Sethi T, Mason E, Bhaskar S, Oluwole O, Pallas C, Ghosh N, Ferdman R, Chen G, Hernandez-Ilizaliturri F, Zurko J, Cunningham A, Shah N, Hu B, Stephens D, Ghosh M, Bailey N, Patel K, Pagel J, Kannan K, Hsi E, Vaidya R, Ip A, Goy A, Kambhampati S, Ohgami R, Andreadis C, Thacker E, Rozzi C, Parker C, Happ L, Dave S. Impact of Molecular Features of Diffuse Large B-Cell Lymphoma on Treatment Outcomes with Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy. Blood 2021, 138: 165. DOI: 10.1182/blood-2021-145764.
- Dittus C, Grover N, Sethi T, Cohen J, Voloschin A, Rabadey J, Tan X, Beaven A, Park S. A Multicenter, Real World Analysis of Primary Central Nervous System Lymphoma in Those with and without Human Immunodeficiency Virus. Blood 2021, 138: 1457. DOI: 10.1182/blood-2021-145133.
- Desai M, Sethi T, Yenamandra A, Morgan D, Thompson M, Reddy N, Kovach A. Primary sinonasal large B cell lymphoma is as histopathologically heterogeneous as systemic large B cell lymphoma but may show subtype-specific tropism for specific sinonasal anatomic sites. Journal Of Hematopathology 2021, 14: 269-275. DOI: 10.1007/s12308-021-00473-5.
- Sethi TK, Montanari F, Foss F, Reddy N. How we treat advanced stage cutaneous T‐cell lymphoma – mycosis fungoides and Sézary syndrome. British Journal Of Haematology 2021, 195: 352-364. PMID: 33987825, DOI: 10.1111/bjh.17458.
- Roy S, Sethi TK, Taylor D, Kim YJ, Johnson DB. Breakthrough concepts in immune-oncology: Cancer vaccines at the bedside. Journal Of Leukocyte Biology 2020, 108: 1455-1489. PMID: 32557857, DOI: 10.1002/jlb.5bt0420-585rr.
- Warner J, Sethi T, Rivera D, Venepalli N, Osterman T, Khaki A, Rubinstein S. Trends in FDA cancer registration trial design over time, 1969-2020. Journal Of Clinical Oncology 2020, 38: 2060-2060. DOI: 10.1200/jco.2020.38.15_suppl.2060.
- Sethi T, Kovach A, Mason E, Chen H, Moyo T, Oluwole O, Morgan D, Reddy N. Combination of Nivolumab, Lenalidomide and Rituximab in Relapsed/Refractory Non-Germinal Center Diffuse Large B Cell Lymphoma: Results from a Dose-Escalation Cohort. Blood 2019, 134: 4100. DOI: 10.1182/blood-2019-129634.
- Epperla N, Costa L, Vaughn J, Hanel W, Raya S, Cashen A, Sarmad R, Badar T, Hamadani M, Liu Y, Barta S, Caimi P, Sethi T, Reddy N, Burkart M, Karmali R, Bello C, Chavez J, Kothari S, Hernandez-Ilizaliturri F, Ballard H, Svoboda J, Emery L, Lansigan F, Glenn M, Churnetski M, Cohen J, Sorge C, Xavier A. Impact of Novel Agents on Outcomes of Patients with Classical Hodgkin Lymphoma and Primary Treatment Failure. Blood 2019, 134: 1554. DOI: 10.1182/blood-2019-129199.
- Sethi TK, Kovach AE, Grover NS, Huang LC, Lee LA, Rubinstein SM, Wang Y, Morgan DS, Greer JP, Park SI, Thompson-Arildsen M, Yenamandra A, Vnencak-Jones CL, Reddy NM. Clinicopathologic correlates of MYD88 L265P mutation and programmed cell death (PD-1) pathway in primary central nervous system lymphoma. Leukemia & Lymphoma 2019, 60: 2880-2889. PMID: 31184237, PMCID: PMC7280020, DOI: 10.1080/10428194.2019.1620942.
- Sethi TK, Morgan D. Hodgkin Lymphoma.J.P. Greer. (2019). Wintrobe’s Clinical Hematology (14th edition). Lippincott Williams & Wilkins (LWW).
- Aghighi M, Theruvath AJ, Pareek A, Pisani LL, Alford R, Muehe AM, Sethi TK, Holdsworth SJ, Hazard FK, Gratzinger D, Luna-Fineman S, Advani R, Spunt SL, Daldrup-Link HE. Magnetic Resonance Imaging of Tumor-Associated Macrophages: Clinical Translation. Clinical Cancer Research 2018, 24: 4110-4118. PMID: 29764855, PMCID: PMC6125171, DOI: 10.1158/1078-0432.ccr-18-0673.
- Treatment of newly diagnosed primary central nervous system lymphoma: current and emerging therapiesSethi TK, Reddy NM. Treatment of newly diagnosed primary central nervous system lymphoma: current and emerging therapies. Leukemia & Lymphoma 2018, 60: 6-18. PMID: 29741421, DOI: 10.1080/10428194.2018.1466296.
- Oke O, Sethi T, Goodman S, Phillips S, Decker I, Rubinstein S, Concepcion B, Horst S, Jagasia M, Kassim A, Harrell SL, Langone A, Lenihan D, Rawling KT, Slosky D, Cornell RF. Outcomes from Autologous Hematopoietic Cell Transplantation versus Chemotherapy Alone for the Management of Light Chain Amyloidosis. Transplantation And Cellular Therapy 2017, 23: 1473-1477. PMID: 28546074, DOI: 10.1016/j.bbmt.2017.05.020.
- Sethi TK, Basdag B, Bhatia N, Moslehi J, Reddy NM. Beyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic Malignancies. Current Hematologic Malignancy Reports 2017, 12: 257-267. PMID: 28233150, DOI: 10.1007/s11899-017-0369-y.
- Sethi T, Reddy N. Current and Emerging Drug Therapies in Chronic Lymphocytic Leukemia. TouchREVIEWS In Oncology & Haematology 2017, 13: 34. DOI: 10.17925/ohr.2017.13.01.34.
- Sethi T, Kovach A, Rubinstein S, Lee L, Wang Y, Morgan D, Greer J, Vnencak-Jones C, Reddy N. Correlation of Toll-like Receptor (TLR) and PD-1 Pathways in Central Nervous System Lymphoma: A Clinicopathological Study on Outcomes. Blood 2016, 128: 929. DOI: 10.1182/blood.v128.22.929.929.
- Sethi T, Nguyen V, Li S, Morgan D, Greer J, Reddy N. Differences in outcome of patients with syncytial variant Hodgkin lymphoma compared with typical nodular sclerosis Hodgkin lymphoma. Therapeutic Advances In Hematology 2016, 8: 13-20. PMID: 28042455, PMCID: PMC5167078, DOI: 10.1177/2040620716676256.
- Sethi T, Nguyen V, Li S, Morgan D, Greer J, Reddy N. Differences in Outcome of Patients with Syncytial Variant Hodgkin Lymphoma (HL) Compared with Typical Nodular Sclerosis HL. Clinical Lymphoma Myeloma & Leukemia 2016, 16: s68-s69. DOI: 10.1016/j.clml.2016.07.100.
- Reddy NM, Sethi TK. Beyond Epstein-Barr virus: genetic predisposition of natural killer T-cell lymphoma. The Lancet Oncology 2016, 17: 1176-1177. PMID: 27470080, DOI: 10.1016/s1470-2045(16)30205-4.
- Aghighi M, Boe J, Rosenberg J, Von Eyben R, Gawande RS, Petit P, Sethi TK, Sharib J, Marina NM, DuBois SG, Daldrup-Link HE. Three-dimensional Radiologic Assessment of Chemotherapy Response in Ewing Sarcoma Can Be Used to Predict Clinical Outcome. Radiology 2016, 280: 905-15. PMID: 26982677, PMCID: PMC5006736, DOI: 10.1148/radiol.2016151301.
- Ukaegbu O, Sethi T, Goodman S, Rubinstein S, Hung R, Jagasia M, Kassim A, Lacy S, Langone A, Lenihan D, Savani B, Slosky D, Cornell R. Autologous Hematopoietic Cell Transplant (AHCT) Offers Prolonged Progression Free and Overall Survival in Patients with Light Chain Amyloidosis (AL) Compared with Chemotherapy Alone. Transplantation And Cellular Therapy 2016, 22: s233-s234. DOI: 10.1016/j.bbmt.2015.11.642.
- Histology-Specific Uses of Tyrosine Kinase Inhibitors in Non-gastrointestinal Stromal Tumor SarcomasSethi TK, Keedy VL. Histology-Specific Uses of Tyrosine Kinase Inhibitors in Non-gastrointestinal Stromal Tumor Sarcomas. Current Treatment Options In Oncology 2016, 17: 11. PMID: 26931561, DOI: 10.1007/s11864-015-0382-0.
- Chen J, Lenihan D, Phillips S, Jagasia M, Goodman S, Kassim A, Lacy S, McDonagh K, Moslehi J, Sethi T, Slosky D, Ukaegbu O, Cornell R. Risk Factors for Cardiac Toxicities Associated with Proteasome Inhibitor Chemotherapy during Treatment of Multiple Myeloma. Blood 2015, 126: 5363. DOI: 10.1182/blood.v126.23.5363.5363.
- Sethi T, Nguyen V, Morgan D, Greer J, Reddy N. Interim Absolute Lymphocyte Count (ALC) As a Predictor of Survival in Hodgkin Lymphoma. Blood 2015, 126: 2640. DOI: 10.1182/blood.v126.23.2640.2640.
- Decker I, Ukaegbu O, Goodman S, Lenihan D, Hung R, Kassim A, Harrell S, McDonagh K, Phillips S, Rawling K, Rubinstein S, Sethi T, Cornell R. Six-Minute Walk Test As a Measure of Functional Change after Chemotherapy in Cardiac AL Amyloidosis. Blood 2015, 126: 1841. DOI: 10.1182/blood.v126.23.1841.1841.
- Sethi T, Nguyen V, Li S, Morgan D, Greer J, Reddy N. Differences in Outcome of Patients with Syncytial Variant Hodgkin Lymphoma (HL) Compared with Typical Nodular Sclerosis HL. Blood 2015, 126: 1441. DOI: 10.1182/blood.v126.23.1441.1441.
- Reddy N, Sethi T. Ibrutinib in chronic lymphocytic leukemia. International Journal Of Hematologic Oncology 2015, 4: 143-150. DOI: 10.2217/ijh.15.15.
- Sethi T, Alireza A, Kloecker G, Slone S. Multicentric Castleman Disease with Complete Duodenal Obstruction in an HIV Patient. Blood 2012, 120: 4834. DOI: 10.1182/blood.v120.21.4834.4834.
- Sethi TK, El-Ghamry MN, Kloecker GH. Radon and lung cancer. Clinical Advances In Hematology And Oncology 2012, 10: 157-64. PMID: 22402423.
- Kaul B, Sivaramakrishnan R, Mahapatra H, Sethi TK, Ahlawat R. Iron deficiency masquerading as idiopathic intracranial hypertension. BMJ Case Reports 2009, 2009: bcr0620080346. PMID: 21686848, PMCID: PMC3028304, DOI: 10.1136/bcr.06.2008.0346.
Departments and Programs
Locations
- Yale HematologySmilow Cancer Hospital at Yale New Haven35 Park StreetNew Haven, CT 06511
- Yale HematologySmilow Cancer Hospital at Yale New Haven35 Park StreetNew Haven, CT 06511